Population pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)

Journal of Clinical Pharmacology

Volumn 53, Issue 7, 2013, Pages 721-730

  Chen, Xuejun ^a,b   Williams, William V ^a   Sandor, Victor ^a   Yeleswaram, Swamy ^a  

^a Clinical Development   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

Myelofibrosis; Population pharmacokinetics; Ruxolitinib

Indexed keywords

ALBUMIN; DIGOXIN; PLACEBO; PREDNISONE; RUXOLITINIB; WARFARIN;

ACCURACY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANALYTICAL ERROR; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; POPULATION MODEL; POST-ESSENTIAL THROMBOCYTOPENIA MYELOFIBROSIS; POSTPOLYCYTHEMIA VERA MYELOFIBROSIS; PREDICTIVE VALUE; THROMBOCYTHEMIA;

AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASES; MALE; MODELS, BIOLOGICAL; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84880321287     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.102     Document Type: Article

References (8)

1. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor RUXOLITINIB: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-3117.
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117-1127.
3. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Presentation on the American Society of Hematology (ASH) annual conference (http://investor.incyte.com/phoenix.zhtml?c69764&pirol-presentations).
4. Adam D. Shilling Frank M. Nedza Thomas EM, et al. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38:2023-2031.
5. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51, 1644-1654.
6. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. Online publication ahead of print, 20 May 2011 (DOI: 10.1177/0091270011405663)
7. Chen X, Shi JG, Emm T, et al. Pharmacokinetics and pharmacodynamics of orally-administered ruxolitinib (INCB 0184 24 phosphate) in renal and hepatic impairment patients (in press).
8. Full prescribing information for JAKAFI. Available at, http://www.incyte.com/products/uspi-jakafi.pdf (last access January 31, 2012).